Acute treatment with relaxin attenuates the injury/ dysfunction induced by renal ischemia/reperfusion injury
Although preclinical and clinical studies have demonstrated that relaxin (RLX) ameliorates impaired renal function by exerting antifibrotic and regenerative effects, its role in renal ischemia/reperfusion (I/R) injury has never been investigated. Using a well-known rat model of 1h bilateral renal artery occlusion followed by 6 h reperfusion, we investigated the effects of human recombinant RLX (5 μg /Kg e.v.) given both at the beginning and after 3 h reperfusion. Serum and urinary indicators of renal injury and dysfunction were measured. Interestingly, administration of the exogenous RLX attenuated all markers of renal injury and dysfunction caused by I/R. Overall, we document here, for the first time, that RLX protects against I/R-induced renal injury and dysfunction. The results of this study offer good perspectives for the clinical potential of RLX in the medical treatment of renal diseases.
This work is licensed under a Creative Commons Attribution 3.0 License.
This work is licensed under a Creative Commons Attribution 4.0 International License (CC-BY- 4.0)
Tel. (0039) 055 2757700 Fax (0039) 055 2757712